AstraZenaca vax halted in Ireland, Denmark, Norway on Sunday. Monday 500,000 more doses in USA

AstraZeneca said on Tuesday that it will supply the U.S. government with an additional 500,000 doses of its experimental, long-acting antibody-based Covid-19 combination treatment that aims to protect those who aren’t able to be vaccinated.

The $205 million agreement to supply the treatment—called AZD7442—builds on a deal the Anglo-Swedish drug manufacturer struck last year with the Department of Health and Human Services and the Department of Defense (DoD).

www.barrons.com/amp/articles/astrazeneca-to-supply-extra-500-000-doses-of-covid-19-treatment-to-u-s-51615897595

Ireland’s health department recommended that the administration of AstraZeneca’s vaccine be “temporarily deferred” immediately on Sunday morning, citing a report from the Norwegian Medicines Agency that highlighted four instances of “serious blood clotting events” in adults who had received the vaccine.

Other countries, including Iceland, Denmark and Norway, suspended their administration of the AstraZeneca vaccine last week on separate concerns over blood clotting, but the World Health Organization and regional authorities have said there is no evidence the vaccines caused the coagulation.

On Saturday, for instance, the Norwegian Institute of Public Health announced that three health workers under the age of 50 were receiving treatment for “severe cases of blood clots or brain haemorrhages” after receiving the AstraZeneca vaccine but reiterated that the conditions were not conclusively linked to the vaccine.

Domestically, the AstraZeneca vaccine is still undergoing phase-three clinical trials and has therefore not been approved by the U.S. Food and Drug Administration, but the New York Times reported Friday that the federal government has purchased roughly 30 million doses that are being packaged in an Ohio facility.

“An analysis of our safety data of more than 10 million records has shown no evidence of an increased risk of pulmonary embolism or deep vein thrombosis in any defined age group, gender, batch or in any particular country with [our] Covid-19 vaccine,” AstraZeneca said in a statement to CNN Friday.

www.forbes.com/sites/jonathanponciano/2021/03/14/astrazeneca-covid-vaccines-blood-clot-concerns/?sh=5c26917cdd71

h/t poopsandwich

864 views

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.